Loading...
Akebia Therapeutics, Inc.
AKBA•NASDAQ
HealthcareBiotechnology
$3.97
$0.28(7.59%)
Akebia Therapeutics, Inc. (AKBA) Financial Performance & Statements
Review Akebia Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-17.70%
↓ 17.70%
Operating Income Growth
-9.11%
↓ 9.11%
Net Income Growth
-33.67%
↓ 33.67%
Operating Cash Flow Growth
-73.88%
↓ 73.88%
Operating Margin
-11.91%
↓ 11.91%
Gross Margin
67.77%
↑ 67.77%
Net Profit Margin
-24.51%
↓ 24.51%
ROE
166.65%
↑ 166.65%
ROIC
-10.06%
↓ 10.06%
Akebia Therapeutics, Inc. (AKBA) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Akebia Therapeutics, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $46.50M | $37.43M | $43.65M | $32.61M |
| Cost of Revenue | $20.36M | $14.16M | $17.45M | $11.97M |
| Gross Profit | $26.13M | $23.27M | $26.20M | $20.64M |
| Gross Profit Ratio | $0.56 | $0.62 | $0.60 | $0.63 |
| R&D Expenses | $11.79M | $8.49M | $7.25M | $9.37M |
| SG&A Expenses | $27.68M | $26.52M | $27.68M | $26.15M |
| Operating Expenses | $40.44M | $35.77M | $34.93M | $35.52M |
| Total Costs & Expenses | $60.80M | $49.93M | $52.37M | $47.48M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $6.88M | $6.66M | $2.15M | $2.50M |
| Depreciation & Amortization | $9.35M | $9.37M | $9.41M | $9.38M |
| EBITDA | -$6.58M | -$4.004M | $2.98M | -$6.11M |
| EBITDA Ratio | -$0.14 | -$0.11 | $0.07 | -$0.19 |
| Operating Income | -$14.31M | -$12.51M | -$8.72M | -$14.88M |
| Operating Income Ratio | -$0.31 | -$0.33 | -$0.20 | -$0.46 |
| Other Income/Expenses (Net) | -$8.50M | -$7.53M | $143000.00 | -$3.05M |
| Income Before Tax | -$22.80M | -$20.04M | -$8.58M | -$17.98M |
| Income Before Tax Ratio | -$0.49 | -$0.54 | -$0.20 | -$0.55 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $9.33M |
| Net Income | -$22.80M | -$20.04M | -$8.58M | -$17.98M |
| Net Income Ratio | -$0.49 | -$0.54 | -$0.20 | -$0.55 |
| EPS | -$0.11 | -$0.10 | -$0.04 | -$0.09 |
| Diluted EPS | -$0.11 | -$0.10 | -$0.04 | -$0.09 |
| Weighted Avg Shares Outstanding | $218.70M | $210.35M | $209.71M | $204.96M |
| Weighted Avg Shares Outstanding (Diluted) | $218.70M | $210.35M | $209.71M | $204.96M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan